New Treatments in Chronic Liver Disease

FRIDAY, MARCH 20 – SUNDAY, MARCH 22, 2015

Pre-Conference: Friday, March 20, 2015
Main Conference: Saturday, March 21 – Sunday, March 22, 2015
Estancia La Jolla • La Jolla, California
Course Introduction

COURSE OVERVIEW

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There was a fundamental change in the treatment of chronic hepatitis C in late 2014 with the addition of multiple new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on currently available all-oral therapies that were approved in late 2014. The second will be on future therapies that will shorten duration and lower cost of a cure. As well, the pre-conference will extensively detail currently available treatment regimens with the goal of introducing the topic to new treaters.

We anticipate that there will be a number of new demands placed on treatment providers, including screening, access to treatment, costs of therapy and the continuation of complex algorithms for interferon-based regimens. Looking beyond 2015, we see numerous combinations of DAA's in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleoside polymerase inhibitors and NS5A inhibitors. Most of these agents are in phase 3 development and a number have completed studies and are awaiting FDA review. In hepatitis B, the treatments have not changed but there is more mature data available on long-term HBsAg loss and clinical outcomes. The addition of immune-mediated therapies for HBV with the goal of curing the disease has been included in this year's program. New therapies for NAFLD and NASH are in development and important new data showing positive results in NASH will be presented at this meeting. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on management of hepatic encephalopathy, hyponatremia and the management of complications in the transplant candidate.

EDUCATIONAL OBJECTIVES

After participating in this course, attendees should be able to:

- Understand the details of the AASLD guidelines for treatment of HCV using DAA's in IFN-free regimens.
- Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions.
- Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals.
- Discuss therapies for HCV including NSSA, protease and polymerase inhibitors.
- Update the skills and management required for transplant hepatology.
- Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
- Discuss future treatment paradigms for HCV direct-acting antiviral drug.
- Describe the diagnosis and treatment of PBC and PSC.
- Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
- Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia.
- Review the management of complications beta-blocker therapy in ESLD.

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Employees of a commercial interest with business lines or products relating to the content of the CME activity will not participate in the planning or any accredited portion of the conference. Disclosure will be made to all participants at the conference location, prior to the educational activity commencement.

COURSE DIRECTOR

Paul Pockros, MD, FACG
Director, Liver Disease Center
Scripps Clinic
Director of Clinical Research
Scripps Translational Science Institute
La Jolla, California

SCRIPPS FACULTY

Catherine Frenette, MD
Medical Director of Liver Transplantation
Director of Center of Excellence for HCC
Scripps Center for Cell and Organ Transplantation
Scripps Clinic
La Jolla, California

Jill Lane, MD
Division of Gastroenterology/Hepatology
Scripps Clinic
La Jolla, California

GUEST FACULTY

Ira Jacobson, MD, FACG
Chief
Division of Gastroenterology and Hepatology
Vincent Astor Distinguished Professor of Medicine
The Joan Sanford I. Weill Medical College of Cornell University
Attending Physician
New York – Presbyterian Hospital, Cornell Campus
New York, New York

Keith Lindor, MD, FACG
Executive Vice Provost and Dean
College of Health Solutions
Arizona State University
Phoenix, Arizona

Rohit Loomba, MD, MHSc
Associate Professor of Clinical Medicine
Director, NAFLD Translational Research Unit
UCSD School of Medicine
La Jolla, CA

Lisa Richards, FNP-BC
Certified Family Nurse Practitioner
University of California San Diego Medical Center
San Diego, California

Bruce Allen Runyon, MD
Clinical Professor of Medicine
Director of Hepatology
UCLA Medical Center
Santa Monica, California

Norman Sussman, MD
Associate Professor, Liver Center
Baylor College of Medicine
Houston, Texas

Tram T. Tran, MD, FACG
Medical Director
Liver Transplant and Hepatology
Associate Professor of Medicine
Cedars Sinai Medical Center
Los Angeles, California

Faculty

Los Angles, California
Cedars Sinai Medical Center
Liver Transplant and Hepatology
Tram T. Tran, MD, FACG
Houston, Texas
Baylor College of Medicine
Associate Professor, Liver Center
Norman Sussman, MD
Santa Monica, California
UCLA Medical Center
Keith Lindor, MD, FACG
New York, New York
Attending Physician
The Joan Sanford I. Weill Medical College of Cornell University
Ira Jacobson, MD, FACG

College of Health Solutions
Arizona State University
Lisa Richards, FNP-BC

Certified Family Nurse Practitioner
University of California San Diego Medical Center
San Diego, California

Ira Jacobson, MD, FACG
Chief
Division of Gastroenterology and Hepatology
Vincent Astor Distinguished Professor of Medicine
The Joan Sanford I. Weill Medical College of Cornell University
Attending Physician
New York – Presbyterian Hospital, Cornell Campus
New York, New York

Keith Lindor, MD, FACG
Executive Vice Provost and Dean
College of Health Solutions
Arizona State University
Phoenix, Arizona

Rohit Loomba, MD, MHSc
Associate Professor of Clinical Medicine
Director, NAFLD Translational Research Unit
UCSD School of Medicine
La Jolla, CA

Lisa Richards, FNP-BC
Certified Family Nurse Practitioner
University of California San Diego Medical Center
San Diego, California

Bruce Allen Runyon, MD
Clinical Professor of Medicine
Director of Hepatology
UCLA Medical Center
Santa Monica, California

Norman Sussman, MD
Associate Professor, Liver Center
Baylor College of Medicine
Houston, Texas

Tram T. Tran, MD, FACG
Medical Director
Liver Transplant and Hepatology
Associate Professor of Medicine
Cedars Sinai Medical Center
Los Angeles, California
**Program**

**Pre-Conference Overview**

We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biopsies and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients during treatment with simeprevir and sofosbuvir, manage side effects of therapy and deal with various patient populations including African Americans, HIV-coinfected and ESLD patients. Lastly, new drugs in development including protease inhibitors, other nucleoside and non-nucleoside polymerase inhibitors, NS5A inhibitors, and other novel agents will be discussed.

**Pre-Conference**

**Friday, March 20, 2015**

- **12:30 p.m.** Registration
- **1 p.m.** Welcome & Introduction  
  *Paul Pockros, MD, FACG*
- **1:10 p.m.** Update on HCV Diagnostics  
  *Paul Pockros, MD, FACG*
- **1:40 p.m.** Update on Current therapy with IFN-free all-oral regimens  
  *Paul Pockros, MD, FACG*

**Saturday, March 21, 2015**

- **7:30 a.m.** Registration, Breakfast & View Exhibits  
  *MODERATOR*  
  *Paul Pockros, MD, FACG*
- **8 a.m.** Welcome & Introduction  
  *30 years of the Scripps Liver Conference*  
  *Paul Pockros, MD, FACG*
- **8:15 a.m.** Beta-Blockers and ESLD Mortality  
  *Bruce Runyon, MD*
- **9 a.m.** New Treatments in Development for NASH  
  *Rohit Loomba, MD, MHSc*
- **9:45 a.m.** Break & View Exhibits
- **10:15 a.m.** Chronic Hepatitis B: Directions Towards A Cure?  
  *Tram Tran, MD*
- **11 a.m.** Debate  
  NASH: Treat Everyone with OCA When It’s Approved  
  *Rohit Loomba, MD, MHSc*  
  NASH: Wait For More Evidence Before Treating with OCA  
  *Bruce Runyon, MD*
- **11:15 a.m.** Panel Discussion: Morning Speakers
- **11:45 a.m.** Lunch  
  *MODERATOR*  
  *Catherine Frenette, MD*  
  *W.S. Haufler Honorary Lecturer*
- **1 p.m.** All-Oral Therapies for HCV  
  *Ira Jacobson, MD, FACG*
- **1:45 p.m.** HCV: What’s Left for Future Treatments?  
  *Paul Pockros, MD, FACG*
- **2:30 p.m.** Break & View Exhibits
- **3 p.m.** Debate #1:  
  Treat HBeAg-negative HBV Forever  
  *Tram Tran, MD*  
  Stop Therapy in HBeAg-negative HBV Patients after Two Years  
  *Paul Pockros, MD, FACG*

**Main Conference**

**Saturday, March 21, 2015**

- **2:40 p.m.** Break & View Exhibits
- **3 p.m.** Pre and Post Liver Transplant  
  *Catherine Frenette, MD*
- **3:30 p.m.** Case Presentation, Discussion and Q&A  
  - Side-Effects Management  
  - Selection of Treatment  
  - Cirrhosis: Who to Treat  
  - Special Populations  
  *Lisa Richards, FNP-BC*
- **3:30 p.m.** Panel Discussion: Afternoon Speakers
- **4:30 p.m.** Adjourn

**Saturday (continued)**

- **3:15 p.m.** Debate #2:  
  HCV: Treat For Cure at Any Cost  
  *Ira Jacobson, MD, FACG*  
  HCV: Treat For Cost-Effective Cure and Salvage Those Who Fail  
  *Paul Pockros, MD, FACG*
- **3:30 p.m.** Panel Discussion: Afternoon Speakers
- **4:30 p.m.** Adjourn

**Sunday, March 22, 2015**

- **7:30 a.m.** Breakfast & View Exhibits  
  *MODERATOR*  
  *Jill Lane, MD*
- **8 a.m.** Emerging Therapies for PBC and PSC  
  *Keith Lindor, MD, FACG*
- **8:45 a.m.** NAFLD: What To Do For The IBS of The Hepatologist?  
  *Norman Sussman, MD*
- **9:30 a.m.** How to Have a Successful Outcome with HCC  
  *Catherine Frenette, MD*
- **10:15 a.m.** Break & View Exhibits
- **10:45 a.m.** Debate  
  Transplant Outcomes Depend on What Region You’re In  
  *Norman Sussman, MD*  
  Transplant Outcomes Depend on Your ICU Care  
  *Catherine Frenette, MD*
- **11 a.m.** Panel Discussion
- **11:45 a.m.** Adjournment
About William S. Haubrich, MD

Dr. Haubrich graduated from Franklin & Marshall College in Lancaster, Pennsylvania in 1943 and from the medical school of Case-Western Reserve University in Cleveland, Ohio in 1947. His postgraduate training in pathology and internal medicine was at Cleveland City Hospital (now MetroHealth). His mentor in gastroenterology was Dr. Henry L. Bockus at the Graduate Hospital of the University of Pennsylvania in Philadelphia. During the Korean War he served as gastroenterologist to the Madigan Army Hospital at Fort Lewis, Washington. From 1955 to 1970 he was on the gastroenterology staff at the Henry Ford Hospital in Detroit. In 1970 he was appointed Clinical Member at the Scripps Clinic and Research Foundation where he headed the division of gastroenterology from 1972 to 1984. He served as Clinical Professor of Medicine at the University of California, San Diego since 1971. His scholarly contributions include more than 200 journal articles and textbook chapters. He was consultant in life sciences to the editors of the 3rd and 4th editions of the American Heritage Dictionary of the English Language. In 1960 he was awarded the Vincent Lyon Prize by the American Gastroenterology Association and in 1985 received the Rudolf Schindler Award of the American Society of Gastrointestinal Endoscopy. He was named a Master of the American College of Physicians. Dr. Haubrich passed away peacefully at his home in La Jolla in October 2012.

Conference Location

Estancia La Jolla Hotel
9700 N. Torrey Pines Road, La Jolla, California 92037
855-318-7602 estancialajolla.com

Please make your own sleeping room reservation, no later than March 3, 2015. Mention you are with the Scripps Liver Disease Conference to receive the reduced rate of $199 per night, plus the $12 hospitality service fee (discounted from $17), which includes: Welcome beverage at check-in, guest room bottled water daily, wireless internet access in guest room and common area, daily newspaper, in room coffee & morning coffee service in Trinitas Cellars Wine Bar, local & 800 call access and access to Fitness Center, Internet Office and Pool area.

Download the Scripps CME App

All conference information including a detailed agenda, faculty listing, faculty disclosures, industry support, attendee list, and course materials can be found on the free Scripps CME conference app for iPhone, iPad, Android, and BlackBerry. To download the app on your smart phone or other device visit the appropriate app store and search ScrippsCME (must be one word). The app is free of charge and will be continuously updated during and after the course.

To access the site using your cell phone or computer’s web browser:
http://www.grupio.com/ScrippsCME

ACCREDITATION

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Breakdown:
Pre-Conference (Fri): 3.5
Main Conference (Sat-Sun): 10

Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credits™. Most states’ Board of Registered Nursing accept AMA PRA Category 1 Credits™ as meeting continuing education requirements for license renewal. Nurses should check with their state board regarding use of CME credit.

Nurse Practitioners: This program will be submitted to the American Association of Nurse Practitioners for continuing education credit.

Physicians Assistants: The American Academy of Physician Assistants accepts Category 1 credit from AMA Category 1 CME organizations accredited by ACCME.

EDUCATIONAL GRANTS

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time of printing, a complete listing of commercial supporters was not available. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.
Conference Fees & Registration

PRE-CONFERENCE FEES
Included: Course tuition, access to conference materials (via mobile app and conference website) and internet in meeting space.

Not Included: Printed course syllabus (presentations available via mobile app and conference website), meals, travel costs, parking and lodging.

<table>
<thead>
<tr>
<th></th>
<th>Thru Feb 23</th>
<th>Feb 24 - Mar 16</th>
<th>On-site after Mar 16</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$100</td>
<td>$125</td>
</tr>
</tbody>
</table>

MAIN CONFERENCE FEES
Included: Course tuition, access to conference materials (via mobile app and conference website) internet in meeting space, breakfast, breaks and lunch.

Not Included: Printed course syllabus (presentations available via mobile app and conference website), travel costs, parking, lodging and dinner.

<table>
<thead>
<tr>
<th></th>
<th>Thru Feb 23</th>
<th>Feb 24 - Mar 16</th>
<th>On-site after Mar 16</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$305</td>
<td>$330</td>
</tr>
<tr>
<td>Physicians</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Physician</td>
<td></td>
<td>$235</td>
<td>$260</td>
</tr>
<tr>
<td>Fellows and Residents</td>
<td></td>
<td>$165</td>
<td>$190</td>
</tr>
</tbody>
</table>

CONFERENCE COURSE MATERIALS
Access to Conference App (included in cost of pre and main conference fees) $100

By completing this registration form and returning it to Scripps you are acknowledging compliance with all attendance policies.

Please Print Clearly. Should we have any conference communications or updates please provide your direct contact information.

Ways to register
Online scripps.org/livercme
Fax 858-652-5565
Mail Scripps Conference Services & CME
Clinical HemOnc
11025 North Torrey Pines Rd.
Suite 200, Maildrop: SCRC 200
La Jolla, California 92037

Attendance Policies
Registration Confirmation
A confirmation letter will be e-mailed to you upon receipt of the conference registration form and payment. If you have not received it within two weeks, please contact the Scripps Conference Services & CME office.

Attendee Cancellation, Substitution, Refund
The course tuition is refundable, minus a $100 processing fee for the main conference ($40 for Fellows and Residents) and $20 processing fee for the pre-conference if your cancellation is received in writing no later than March 18, 2015. Attendee substitutions are allowed, but notification must be made in writing by March 18, 2015. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to “no shows.”

Payment Method
Check, Please make checks payable to Scripps (in U.S. dollars only).

If paying by credit card, please fill out the information below. Visa MasterCard Amex Discover

[Credit Card Information]

[Assistant Contact Information]

PLEASE INDICATE ANY SPECIAL NEEDS (INCLUDING DIETARY RESTRICTIONS)
Special requests will be considered and accommodated in full compliance with the Americans with Disabilities Act (ADA).

Payment method ___, Check, Please make checks payable to Scripps (in U.S. dollars only).
New Treatments in Chronic Liver Disease

March 20-22, 2015

Pre-Conference: Fri., March 20, 2015
Main Conference: March 21 - Sunday, March 22, 2015
Estancia La Jolla, La Jolla, California

2015 Conference Highlights

- Conference presentations will be available via mobile app and conference website. Internet will be available in the meeting space.
- Half Day Pre-Conference Seminar reviewing the virology, genotypes and modes of infection of HCV. Participants will learn the details of new AASLD guidelines for treatment of HCV using DAA’s in combination with pegylated interferon and ribavirin.
- Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.
- Endorsed by the American College of Gastroenterology.
- Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.

Target Audience

Hepatologists
Gastroenterologists
Infectious Disease Specialists
Nurse Practitioners
Physician Assistants
Nurses
Residents/Fellows
and others desiring an update in these specialty areas